Breaking News

Alchemia Names CEO

By Kristin Brooks | February 24, 2014

Liquard brings commercial and managerial expertise from Pfizer

Thomas Liquard has been appointed chief executive officer of Alchemia, following the departure of Charles Walker. Mr. Liquard joined the company in December 2013 as chief operating officer, and brings significant commercial and managerial expertise having most recently served as senior director of Portfolio Development Lead Emerging Markets for the Established Products portfolio at Pfizer.
Mr. Liquard spent seven years at Pfizer holding various commercial roles of increasing responsibility. Mr. Liquard was a key member of the EP U.S. Brands P&L Leadership Team, where he planned the group's investment strategy culminating in the acquisition of NextWave Pharmaceuticals. Mr. Liquard also served in the New Product Planning and Portfolio Decision & Analysis organizations, where he was responsible for investment decisions on business development opportunities and internal development programs across multiple therapeutic areas including oncology, CNS and metabolic diseases.
"The company has been diligently preparing for its transformation into a broader commercial organization and with our pivotal Phase III trial data read-out on the horizon for HA-irinotecan, along with a developing oncology pipeline, we are delighted to make this appointment," said Santo J. Costa, Alchemia's incoming chairman. "Thomas' impressive background and strategic mindset makes him extremely qualified to lead Alchemia through this next stage of corporate growth. On behalf of the Board, I wish to thank Charlie for his service over the last year in helping guide our transition to products beyond fondaparinux."

blog comments powered by Disqus
  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important

  • Moore’s Law for More Health

    Moore’s Law for More Health

    Patrick Jordan , Encore Health Resources||June 2, 2015
    This year marks the semicentennial anniversary of a prediction about exponential growth and productivity